RADIATION THERAPY ONCOLOGY GROUP
RTOG 1216
RANDOMIZED PHASE II/III TRIAL OF SURGERY AND POSTOPERATIVE RADIATION DELIVERED WITH CONCURRENT CISPLATIN VERSUS DOCETAXEL VERSUS DOCETAXEL AND CETUXIMAB FOR HIGH-RISK SQUAMOUS CELL CANCER OF THE HEAD AND NECK
RTOG 1216
RANDOMIZED PHASE II/III TRIAL OF SURGERY AND POSTOPERATIVE RADIATION DELIVERED WITH CONCURRENT CISPLATIN VERSUS DOCETAXEL VERSUS DOCETAXEL AND CETUXIMAB FOR HIGH-RISK SQUAMOUS CELL CANCER OF THE HEAD AND NECK
Protocol Participation Information
- Credentialing Requirements
- Facility Questionnaire: Part I and Part II are required for this protocol.
- Download fillable forms and complete them.
- Submit to RTOG RT Quality Assurance Department
Email: rtog-facquest@phila.acr.org Fax: 215-940-8817
- RPC Phantom Dosimetry Test (IMRT only)
- Fill out the RPC Phantom Request Form to request shipment of a phantom.
- Phantom irradiation guidelines and forms (contact RPC at 713-745-8989 with questions)
- Contact Bill Straube at 314-362-9762 regarding submission of phantom treatment planning data to the ITC.
- ITC Digital Data Submission Test
- Contact Bill Straube at 314-362-9762 for instructions.
- How to Participate
- Structure Names - Please refer to protocol text for structure naming requirements.
- Study Details Page (http://www.rtog.org)
PLEASE NOTE: This protocol has been amended to require treatment planning data submission via the TRIAD system. Cases with case numbers above 8 are to be submitted via TRIAD at RTOG HQ. Please see section 12.2 of the protocol for information on TRIAD.
Back to protocols
